Mayo Clinic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mayo Clinic sits in the top decile of US sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count).
Mayo Clinic: 2,844 sponsored US clinical trials, 544 recruiting.
Mayo Clinic sponsors 2,844 registered US clinical trials on ClinicalTrials.gov, 544 of them currently recruiting, and 1,816 completed. 252 of these trials are in Phase 3-4 (later-stage) and 821 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 36 trials.
Top-decile sponsor footprint
Mayo Clinic ranks in the top decile of sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,844 total, page 14 of 57
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
NCT03737695
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT03941730
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
NCT03879629
Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss
NCT03238794
Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study
NCT03778060
Fecal Incontinence Treatment (FIT) Study
NCT03811821
Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy
NCT03946618
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
NCT03573349
Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis
NCT03841279
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
NCT03584022
Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA
NCT03608579
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
NCT03554083
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT06339138
A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
NCT03902600
HELP-HY: Health Education and sLeep Program in HYpertension
NCT03255746
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
NCT03197506
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
NCT03281902
CREST: Capsular Repair During Hip Arthroscopy
NCT03372564
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
NCT03268603
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT03120624
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
NCT03179904
Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
NCT02808208
Ovarian Tissue Cryopreservation in Children
NCT02646384
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03021460
Evaluating Raised Intracranial Pressure Using MR Elastography
NCT03096743
Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy
NCT03017794
Use of a Squatting Assist Device in Patients With Constipation
NCT02877394
Neural Circulatory Control and SUDEP Risk.
NCT02813980
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
NCT02740634
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
NCT02457962
Exparel Injection for Postoperative Orbital Pain
NCT02381353
Extracellular RNA Markers of Liver Disease and Cancer
NCT02908048
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT02068794
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
NCT02104310
Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study
NCT02047396
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
NCT01953640
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
NCT01787409
MR-Guided Cryoablation of Prostate Bed Recurrences
NCT01727284
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
NCT02315027
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma
NCT00835133
Virtual Assistant for Plastic Surgery Patients
NCT04017351
Evaluation of a Digital Visual Acuity Device vs. Standard Visual Acuity Measurements
NCT06431295
A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
NCT07126548
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
NCT07221656
The Effect of Dry Needling With Electrical Stimulation on Individuals With Restless Legs Syndrome
NCT05860751
Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications
NCT06649864
The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, Biomechanics, and Pain Intensity
NCT06891001
A Study of the Effect of a Nurse Navigator Program on High Risk Patients
NCT05592847
Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy
NCT07086183
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
NCT07206589
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 435 |
| Phase 2 | 386 |
| Phase 3 | 86 |
| Phase 4 | 166 |
Therapeutic Areas
What is open in the Mayo Clinic pipeline
544 recruiting of 2,844 indexed (19% open); 1,816 completed (64%).
Phase mix: 252 late (III/IV) vs 821 early (I/II) (early-phase heavy).
Top condition: Healthy (36 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.